静脉溶栓前后应用瑞舒伐他汀对急性脑梗死患者的疗效和安全性分析

Efficacy and Safety of Rosuvastatin in Patients with Acute Cerebral Infarction before and after Intravenous Thrombolysis

目的该次实验将分析静脉溶栓前后应用瑞舒伐他汀对急性脑梗死患者的疗效,以及是否具有安全性上的保障。方法该次实验选取了2019年1—7月前来该院就诊的患者,其均为急性脑梗死人群,在自愿参与实验调查的基础上选取18例患者作为调研对象。在分组上,为保证公平性为随机分组。对照组患者在静脉溶栓后实施瑞舒伐他汀,观察组则为溶栓前实施瑞舒伐他汀,对比应用的效。结果从治疗质量上看,观察组患者在NIHSS评分、ADL-Barthel指数评分上分别为(2.33±0.25)分和(72.36±10.61)分,对照组为(4.36±0.52)分和(63.33±8.45)分,组间对比差异有统计学意义(t=3.254、4.589,P<0.05)。与此同时,在HMGB1、MMP-9及IL-17水平对比分析中,观察组的治疗效果也优于对照组,差异有统计学意义(P<0.05)。此外,对比患者的预后良好率,在第1周和第8周的时候观察组的良好率分别为44.4%(4/9)和88.9%(8/9),对照组则为33.3%(3/9)和55.6%(5/9),最后,在安全性分析中,两组患者的差异性较小,可以给予安全性上的保障。因此,该研究认为观察组的应用方式更佳。结论在静脉溶栓前应用瑞舒伐他汀对急性脑梗死患者的疗效具有积极效果,有利于改善患者的神经功能,提升生活质量,并能够控制好颅内出血的发生率,具有良好的安全性保障,整体应用效果好,值得推广。

Objective This experiment will analyze the efficacy of rosuvastatin in patients with acute cerebral infarction before and after intravenous thrombolysis,and whether it is safe.Methods This study selected patients who came to the hospital from January to July 2019.All of them were acute cerebral infarction.18 patients were selected as subjects for investigation based on voluntary participation in the experimental investigation.In order to ensure fairness is a random grouping.In the control group,rosuvastatin was administered after intravenous thrombolysis,and in the observation group,rosuvastatin was administered before thrombolysis,and the effect was compared.Results From the treatment quality,the NIHSS score and ADL-Barthel index scores were(2.33±0.25)points and(72.36±10.61)points,respectively,and the control group was(4.36±0.52)points and(63.33±8.45)points,the difference between groups was significant,with statistical significance(t=3.254,4.589,P<0.05).At the same time,in the comparative analysis of HMGB1,MMP-9 and IL-17 levels,the therapeutic effect of the observation group was also superior to that of the control group,and the difference was statistically significant(P<0.05).In addition,we compared the prognosis of the patients.The good rates of the observation group were 44.4%(4/9)and 88.9%(8/9)in the first week and the eighth week,respectively,and 33.3%in the control group(3/9)and 55.6%(5/9).Finally,in the safety analysis,the difference between the two groups of patients was small and safety protection could be given.Therefore,we believe that the observation group is applied in a better way.Conclusion The application of rosuvastatin before intravenous thrombolysis has a positive effect on patients with acute cerebral infarction,which is beneficial to improve the neurological function of patients,improve the quality of life,and control the incidence of intracranial hemorrhage.It has good safety.The overall application effect is good,it is worth promoting.